My mistake did not know I would be need to explain the entire news article. Next time I will just post the link to the news.
P.S you made my iggy list no need to ramble on about nothing. I would rather waste my time talking to a monkey.
So, do you think BSX stock price is getting ready to head south? If you draw a line from the two high points ($6.41 to $6.28) on the chart and intersect them on Wednesday price, then it hit it's maximum high, (or within a couple of cents).
But like anything else it could go higher just on emotion or news.
I guess you would have to tell me what I am distorting. The reduction in special charges was in the news release. You are leaving that out of your pump. That is deception at least.
I just find it odd that in order to accompish your pump you have to use only partial information to make your point. You are out leaving material facts. For people who read the articles, it appears like you are insulting their intelligence, which hurts your credibility.
If that's how you want to operate - your call.
Nice try dopey. Your choice to be as lame as you want to be. You are a biased pumper.
So, you say that profit increased due to operations vs. reduction in special (dysfunctional)charges is equal. OK. You should do a book. Here is the title:
"How to make $ in the stock market by finding companies who have reduced their dysfunctional special charges."
I have never seen a book of that title. It would be a first. You could make your millions on that. I won't even ask for any royalties.
these are the material facts, based on real math, not your Mississippi math:
"US CRM sales were down 14% this quarter, worse than St. Jude's (-7%) performance (and Medtronic (MDT ) won't report for a while). ICD revenue fell 12% (St. Jude's fell 2%), indicating that BSX continues to lose share despite some controversy with St. Jude's leads."
"Global sales of coronary stent system (within Interventional Cardiology) at $387 million declined 5.8% due to disappointing performance from both drug-eluting stents (“DES”) that declined 4.2% to $363 million and bare-metal stents that plunged 20% to $24 million."
Whatever profits they made, they just flushed it down the toilet in buying a start-up company with a POS ICD. BSX is paying $1.35 billion for an ICD that the FDA has already said they will not approve it:
To add on to the list of woes, now it turns out there was a defective transformer used in Cognis and Teligen ICDs, and these have been implanted in 233,000 patients. This is going to result in more lawsuits against the company, costing them at least hundreds of millions of dollars:
So whatever "profit" this company may have made through layoffs and cost-cutting, the profits have been flushed down the toilet, and then some!
Look fellow I do not care what you label me. Stated some Material facts about the stock that was already reported in the News after the companies earnings release.
Sounds like you and a few others are trying to distort the material facts to your benefit.
Profits more than doubled. That is a material fact.